Next Article in Journal
Lipid Droplets Define a Sub-Population of Breast Cancer Stem Cells
Next Article in Special Issue
Ontogenetic Pattern Changes of Nucleobindin-2/Nesfatin-1 in the Brain and Intestinal Bulb of the Short Lived African Turquoise Killifish
Previous Article in Journal
Maxillary Antrostomy Patency Following Intraoperative Use of Spray Cryotherapy
Previous Article in Special Issue
The Reeler Mouse: A Translational Model of Human Neurological Conditions, or Simply a Good Tool for Better Understanding Neurodevelopment?
Open AccessReview

Radiolabeled PET/MRI Nanoparticles for Tumor Imaging

1
IRCCS SDN, Via Gianturco 113, 80143 Naples, Italy
2
Department of Chemical Engineering, Materials and Industrial Production, University of Naples Federico II, P.le Tecchio 80, 80125 Naples, Italy
3
Istituto Italiano di Tecnologia, IIT—Center for Advanced Biomaterials for Health Care, [email protected], Largo Barsanti e Matteucci, 80125 Naples, Italy
4
Interdisciplinary Research Center on Biomaterials, CRIB, University of Naples Federico II, P.le Tecchio 80, 80125 Naples, Italy
*
Author to whom correspondence should be addressed.
Both authors equally contributed to this manuscript.
J. Clin. Med. 2020, 9(1), 89; https://doi.org/10.3390/jcm9010089
Received: 19 November 2019 / Revised: 23 December 2019 / Accepted: 24 December 2019 / Published: 29 December 2019
(This article belongs to the Special Issue Cutting Edge Preclinical Models in Translational Medicine)
The development of integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) scanners opened a new scenario for cancer diagnosis, treatment, and follow-up. Multimodal imaging combines functional and morphological information from different modalities, which, singularly, cannot provide a comprehensive pathophysiological overview. Molecular imaging exploits multimodal imaging in order to obtain information at a biological and cellular level; in this way, it is possible to track biological pathways and discover many typical tumoral features. In this context, nanoparticle-based contrast agents (CAs) can improve probe biocompatibility and biodistribution, prolonging blood half-life to achieve specific target accumulation and non-toxicity. In addition, CAs can be simultaneously delivered with drugs or, in general, therapeutic agents gathering a dual diagnostic and therapeutic effect in order to perform cancer diagnosis and treatment simultaneous. The way for personalized medicine is not so far. Herein, we report principles, characteristics, applications, and concerns of nanoparticle (NP)-based PET/MRI CAs. View Full-Text
Keywords: multimodal imaging; hybrid imaging; positron emission tomography/magnetic resonance imaging (PET/MRI), nanotechnology; nanoparticles; in vivo imaging; 3D reconstruction multimodal imaging; hybrid imaging; positron emission tomography/magnetic resonance imaging (PET/MRI), nanotechnology; nanoparticles; in vivo imaging; 3D reconstruction
Show Figures

Figure 1

MDPI and ACS Style

Forte, E.; Fiorenza, D.; Torino, E.; Costagliola di Polidoro, A.; Cavaliere, C.; Netti, P.A.; Salvatore, M.; Aiello, M. Radiolabeled PET/MRI Nanoparticles for Tumor Imaging. J. Clin. Med. 2020, 9, 89.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop